Référentiel des médicaments
Selexipag
Selexipag is a medicine in the class cardiovascular. It is used for pulmonary hypertension.
- Classe médicamenteuse: Cardiovascular
- Indications: pulmonary hypertension
Dernière mise à jour Sources: US FDA label, EMA SmPC
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Cardiovascular
- Code ATC
- B01AC27
- Formes courantes
- comprimé, injection
- Dosages courants
- 1000 mcg
- Interactions connues
- 36 (Contre-indiquée: 1 · Modérée: 20 · Mineure: 15)
- Noms commerciaux
- 3
- Pays et marchés
- 3
Indications
Mécanisme d'action
Selexipag is a prostacyclin (IP) receptor agonist, structurally distinct from prostacyclin. It is hydrolyzed by carboxylesterase 1 to an active metabolite that is approximately 37-fold as potent as selexipag.
Posologie adulte habituelle (résumé de la notice)
PAH (tablets): start 200 mcg orally twice daily; increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1,600 mcg twice daily; if a dose is not tolerated, reduce to the previous tolerated dose
Grossesse et allaitement
- Grossesse
- Unknown No adequate and well-controlled studies in pregnant women. Animal studies showed no clinically relevant effects on embryofetal development.
- Allaitement
- Unsafe Not known whether present in human milk; present in rat milk. Discontinue nursing or discontinue UPTRAVI.
Effets indésirables signalés
- Headache
- Diarrhea
- Nausea
- Jaw pain
- Vomiting
- Pain in extremity
Contre-indications
- Hypersensitivity to the active substance or any excipients
- Concomitant use of strong CYP2C8 inhibitors (e.g., gemfibrozil)
Précautions particulières
- Pulmonary edema may signal pulmonary veno-occlusive disease; if confirmed, discontinue.
- Pediatric patients had smaller mean increases in weight and height than placebo; monitor growth.
- Hyperthyroidism was observed in 1% of adults on tablets and in none on placebo.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (36)
- Gemfibrozil + Selexipag Contraindicated
- Abiraterone + Selexipag Moderate
- Apalutamide + Selexipag Moderate
- Carbamazepine + Selexipag Moderate
- Clopidogrel + Selexipag Moderate
- Cyclosporin + Selexipag Moderate
- Deferasirox + Selexipag Moderate
- Eltrombopag + Selexipag Moderate
- Lapatinib + Selexipag Moderate
- Losartan + Selexipag Moderate
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Selexipag : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
- IV preparation and dilution
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Questions fréquentes
What is Selexipag used for?
Selexipag is a medicine in the class cardiovascular. It is used for Pulmonary hypertension.
What side effects have been reported with Selexipag?
Headache, Diarrhea, Nausea, Jaw pain, Vomiting, Pain in extremity.
Can Selexipag be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. No adequate and well-controlled studies in pregnant women. Animal studies showed no clinically relevant effects on embryofetal development. Breastfeeding: Unsafe. Not known whether present in human milk; present in rat milk. Discontinue nursing or discontinue UPTRAVI.
What does Selexipag interact with?
MediHelp lists 36 known interactions for Selexipag. Contraindicated: 1 · Moderate: 20 · Minor: 15. The most serious include Gemfibrozil, Abiraterone, Apalutamide.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
